Hematologic Malignancy
Myeloid Leukemia
CI-CAN-00001251Explore in graph →
Hematologic862 active trials22 approved drugs599 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001251Explore in graph →
Clinical trials
3,528 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (617)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00093990 | Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) | completed | Phase 3 | 457 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 0 | Sep 14, 2016 | clinicaltrials |
| NCT00123474 | Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML | completed | Phase 3 | 724 | Bristol-Myers SquibbINDUSTRY | 31 | Aug 25, 2016 |
| NCT00476541 | NOPHO-AML 2004 Study for Children With Acute Myeloid Leukemia | completed | Phase 3 | 250 | University of AarhusOTHER | 1 | May 13, 2016 | clinicaltrials |
| NCT01275196 | Safety and Efficacy of Nilotinib vs. Imatinib in the Treatment of Newly Diagnosed Chinese Ph+ CML-CP Patients | completed | Phase 3 | 267 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 8, 2016 | clinicaltrials |
| NCT00495287 | A Remission Induction Therapy and Risk-oriented Postremission Strategy for Adult Acute Myelogenous Leukemia (AML) | completed | Phase 3 | 573 | Northern Italy Leukemia GroupOTHER | 1 | Mar 31, 2016 | clinicaltrials |
| NCT01254188 | Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients(ENESTxtnd) | completed | Phase 3 | 421 | Novartis PharmaceuticalsINDUSTRY | 19 | Mar 3, 2016 | clinicaltrials |
| NCT01511289 | Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients | completed | Phase 3 | 242 | Il-Yang Pharm. Co., Ltd.INDUSTRY | 4 | Feb 24, 2016 | clinicaltrials |
| NCT00802841 | Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib(LASOR) | completed | Phase 3 | 191 | Novartis PharmaceuticalsINDUSTRY | 12 | Nov 16, 2015 | clinicaltrials |
| NCT00469729 | Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy(ExCell) | completed | Phase 2 / Phase 3 | 101 | Gamida Cell -Teva Joint Venture Ltd.OTHER | 5 | Jul 10, 2015 | clinicaltrials |
| NCT02461121 | HLA-mismatched MST vs HLA-matched NST for AML in Intermediate-risk | completed | Phase 3 | 156 | The Affiliated Hospital of the Chinese Academy of Military Medical SciencesOTHER | 1 | Jun 4, 2015 | clinicaltrials |
| NCT00678275 | Chronic Graft-versus-host Disease (cGvHD) Prophylaxis With or Without ATG Prior to Stem Cell Transplantation (SCT) From HLA-identical Siblings in Patients With Acute Leukemia | completed | Phase 3 | 161 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | May 13, 2015 | clinicaltrials |
| NCT00123487 | Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML | completed | Phase 3 | 638 | Bristol-Myers SquibbINDUSTRY | 32 | Nov 3, 2014 | clinicaltrials |
| NCT00322101 | Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia | completed | Phase 3 | 25 | Fred Hutchinson Cancer CenterOTHER | 2 | Oct 31, 2014 | clinicaltrials |
| NCT02103322 | Comparative Bioequivalence Study in Adult Patients Suffering From Chronic Myeloid Leukemia & Gastrointestinal Stromal Tumor Under Fed Conditions | completed | Phase 2 / Phase 3 | 48 | Amneal Pharmaceuticals, LLCINDUSTRY | 1 | Jun 27, 2014 | clinicaltrials |
| NCT00909168 | Induction, Consolidation and Intensification Therapy for Patients Younger Than 66 Years With Previously Untreated CD33 Positive Acute Myeloid Leukemia (AML)(MYFLAI07) | completed | Phase 2 / Phase 3 | 130 | University Hospital, Udine, ItalyOTHER | 1 | May 6, 2014 | clinicaltrials |
| NCT00317642 | A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I) | completed | Phase 3 | 326 | Genzyme, a Sanofi CompanyINDUSTRY | 5 | Apr 14, 2014 | clinicaltrials |
| NCT00590837 | Adding Lomustine to Chemotherapy in Older Patients With Acute Myelogenous Leukemia (AML), and Allogeneic Transplantation for Patients From 60 to 65 Years Old(LAM-SA 2007) | completed | Phase 3 | 459 | University Hospital, BordeauxOTHER | 1 | Apr 2, 2014 | clinicaltrials |
| NCT00428558 | Timed-Sequential Induction in CBF-AML | completed | Phase 3 | 200 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Dec 20, 2013 | clinicaltrials |
| NCT01110824 | Prevention of Left Ventricular Dysfunction During Chemotherapy(OVERCOME) | completed | Phase 3 | 90 | Hospital Clinic of BarcelonaOTHER | 1 | Nov 15, 2013 | clinicaltrials |
| NCT00333840 | Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia | completed | Phase 3 | 1,106 | Novartis PharmaceuticalsINDUSTRY | 16 | Oct 14, 2013 | clinicaltrials |
| NCT01147939 | Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML)(CLAVELA) | completed | Phase 3 | 381 | Clavis PharmaINDUSTRY | 13 | Sep 27, 2013 | clinicaltrials |
| NCT00927498 | A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old | completed | Phase 3 | 280 | Acute Leukemia French AssociationOTHER | 1 | Jul 11, 2013 | clinicaltrials |
| NCT00003934 | Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia | completed | Phase 3 | 420 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00003190 | Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia | completed | Phase 3 | 640 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00006363 | Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia | completed | Phase 3 | 720 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT01188798 | Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies | completed | Phase 3 | 6 | St. Jude Children's Research HospitalOTHER | 1 | Mar 21, 2013 | clinicaltrials |
| NCT00398983 | Randomized Study of Decitabine in Maintenance Therapy of Acute Myeloid Leukemia (AML) | completed | Phase 2 / Phase 3 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 4, 2013 | clinicaltrials |
| NCT00002798 | Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome | completed | Phase 3 | 880 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00266136 | Biology and Treatment Strategy of AML in Its Subgroups: Multicenter Randomized Trial by the German Acute Myeloid Leukemia Cooperative Group (AMLCG) | completed | Phase 3 | 3,500 | University Hospital MuensterOTHER | 1 | Oct 26, 2012 | clinicaltrials |
| NCT00799461 | Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications | completed | Phase 3 | 1,337 | Fred Hutchinson Cancer Research Center/University of Washington Cancer ConsortiumOTHER | 1 | Mar 7, 2012 | clinicaltrials |
| NCT00422890 | Treatment of Imminent Haematological Relapse in Patients With AML and MDS Following Allogeneic Stem Cell Transplantation With 5-azacitidine (Vidaza®) | completed | Phase 3 | 10 | Technische Universität DresdenOTHER | 1 | Jul 11, 2011 | clinicaltrials |
| NCT00474006 | High Dose Daunorubicin Vs. Standard Dose Daunorubicin in Induction Treatment of AML(ADcomparison) | completed | Phase 3 | 398 | Cooperative Study Group A for HematologyNETWORK | 1 | Jun 10, 2011 | clinicaltrials |
| NCT00521664 | A Trial Comparing a Prophylactic With a Therapeutic Platelet Transfusion Strategy in Two Groups | completed | Phase 3 | 400 | Technische Universität DresdenOTHER | 1 | May 19, 2011 | clinicaltrials |
| NCT00186966 | Treatment of Children and Adolescents With Refractory or Relapsed Acute Myeloid Leukemia | completed | Phase 3 | 394 | Dutch Childhood Oncology GroupOTHER | 1 | Apr 6, 2011 | clinicaltrials |
| NCT01020175 | Peripheral Blood (PB) Versus Bone Marrow (BM) in Allogeneic Stem Cell Transplantation | completed | Phase 3 | 350 | European Society for Blood and Marrow TransplantationNETWORK | 1 | Nov 25, 2009 | clinicaltrials |
| NCT01015196 | Prospective Randomized Study Comparing One or Two High Dose Chemotherapy Regimen Followed by Autologous Stem Cell Transplantation(AML2001) | completed | Phase 2 / Phase 3 | 832 | Nantes University HospitalOTHER | 1 | Nov 18, 2009 | clinicaltrials |
| NCT00931138 | Treatment of Acute Myeloid Leukemia (AML) in Adults 50 to 70 Years, Study of Two Anthracyclines and the Interest of Maintenance Treatment With Interleukin 2(ALFA 9801) | completed | Phase 3 | 420 | Acute Leukemia French AssociationOTHER | 1 | Jul 2, 2009 | clinicaltrials |
| NCT00925873 | GOELAMS SA4 Study: the Role of Fludarabine in the Treatment of Acute Myeloid Leukemia in the Elderly | completed | Phase 3 | 303 | French Innovative Leukemia OrganisationOTHER | 1 | Jun 22, 2009 | clinicaltrials |
| NCT00880243 | Effect of Priming During Induction and Consolidations in Younger Acute Myeloid Leukemia (AML) | completed | Phase 3 | 473 | Acute Leukemia French AssociationOTHER | 0 | Apr 13, 2009 | clinicaltrials |
| NCT00146120 | Risk-Adapted Therapy of Acute Myeloid Leukemia of Adults (18-60 Years) According to the Cytogenetic Result | completed | Phase 3 | 400 | University of UlmOTHER | 2 | Feb 9, 2009 | clinicaltrials |
| NCT00152139 | Stem Cell Transplantation for Patients With Hematologic Malignancies | completed | Phase 3 | 33 | St. Jude Children's Research HospitalOTHER | 1 | Jan 29, 2009 | clinicaltrials |
| NCT00700544 | Treatment Outcome in Elderly Patients | completed | Phase 3 | 330 | University Hospital, GrenobleOTHER | 1 | Jun 18, 2008 | clinicaltrials |
| NCT00514488 | Imatinib Standard Dose (400 mg/Day) Versus Imatinib High Dose (800 mg/Day)(CML022) | completed | Phase 3 | — | University of BolognaOTHER | 1 | Aug 10, 2007 | clinicaltrials |
| NCT00480064 | Lomustine and Intermediate Dose Cytarabine in Older Patients With AML | completed | Phase 3 | 360 | French Innovative Leukemia OrganisationOTHER | 1 | May 30, 2007 | clinicaltrials |
| NCT00300664 | A Randomized Trial of Human Growth Hormone (hGH) vs Placebo in Intensively Treated Haemato-Oncology Patients. | completed | Phase 2 / Phase 3 | 150 | Royal Marsden NHS Foundation TrustOTHER | 0 | Oct 13, 2006 | clinicaltrials |
Data updated 22 days agoSource updated Sep 14, 2016source: clinicaltrials